comparemela.com

Latest Breaking News On - புற்றுநோய் நிறுவனம் மருத்துவமனை - Page 1 : comparemela.com

Changes in Treatment Behavior during the COVID-19 Pandemic

Feb 22, 2021 This study was conducted to analyse the changes in Treatment Behavior during the COVID-19 Pandemic among Patients at a Cancer Hospital. The number of new outpatients and patients receiving surgery at a cancer hospital in Japan drastically decreased under and even after the state of emergency. SARS-CoV-2 infection can result in severe COVID-19 and high mortality among cancer patients. This indicates that patients without established care patterns lost opportunities for cancer diagnosis and treatment. Emergency measures were first implemented in Tokyo and six other prefectures. As it was previously reported, the incidence of COVID-19 among cancer patients was low, even for symptomatic patients with typical computed tomography findings. The patient behavioral changes related to treatment during the pandemic in cancer hospitals have not been thoroughly investigated. 

Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Calquence approved in Japan for CLL

  relapsed or refractory chronic lymphocytic leukaemia   progression after 12 months vs. 68% for comparators   AstraZeneca s Calquence (acalabrutinib), a next-generation, selective Bruton s tyrosine kinase (BTK) inhibitor, has been approved in Japan for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) (including small lymphocytic lymphoma [SLL]).   The approval by the Japanese Ministry of Health, Labour and Welfare was based on positive results from the ASCEND Phase III trial and a Phase I trial in Japanese patients, showing Calquence monotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus a standard treatment of rituximab, a monoclonal antibody, combined with the physician s choice of idelalisib, a PI3-kinase inhibitor or bendamustine, a chemotherapy.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.